Skip to main content

Table 2 Description of harm reduction services regularly provided by centres and number of users per centre (n = 11) during the first 6 months of the years 2019 and 2020, Spain (n = 11)

From: The impact of the COVID-19 pandemic on harm reduction services in Spain

Centre
(city name)
n. users 2019
(Jan–June)
n. users 2020
(Jan–June)
NSP SIR Naloxone distribution Education services Mental health services OST HCV DAA HIV ART HBV testing HCV testing HIV testing TB testing
Centre 1 (Badalona) 265 274          
Centre 2 (Bilbao) 923 721         
Centre 3
(Madrid)
4528 1945  
Centre 4
(Madrid)
892 1090  
Centre 5
(Vitoria-Gasteiz)
77 60           
Centre 6
(Bilbao)
1267 1080       
Centre 7
(Reus)
394 398         
Centre 8
(Valencia)
764 687   
Centre 9
(Bilbao)
1365 679           
Centre 10
(El Prat de Llobregat)
2652 3351        
Centre 11
(Barcelona)
N/A N/A    
Centre 12
(Barcelona)
N/A N/A  
Centre 13
(Sant Adrià de Besos)
6166 3912       
Total    13 4 8 12 13 7 7 5 6 9 9 6
  1. NSP Needle and syringe programme, SIR supervised injecting room, OST opioid substation therapy, DAA direct acting antivirals, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus (HIV), TB tuberculosis, N/A not available